帕金森病多巴胺神经元成像生物标志物量化 harmonization:Centamine 量表
本研究提出 Centamine 框架,用于统一量化多巴胺能分子成像示踪剂(如 [123I]ioflupane SPECT 和 [18F]AV133 PET)所评估的多巴胺神经元丢失。框架分三个分析层级,利用健康受试者数据建立 Centamine 量表,并通过头对头数据将其他示踪剂映射到该量表。结果显示 [123I]ioflupane SPECT 与 [18F]AV133 PET 在 5 个脑区呈中强线性相关(R²=0.51-0.83),映射后的 Centamine 值差异较小(1.5%-3%)。
要点
- Centamine 量表基于健康受试者 [123I]ioflupane SPECT 数据建立。
- 通过头对头数据可将 [18F]AV133 PET 等示踪剂映射到 Centamine 量表。
- 不同示踪剂映射后的 Centamine 值差异较小,支持 harmonization。
核心结论
- Centamine 量表有望实现多巴胺神经元成像标志物的统一量化,并加速帕金森病临床试验。
研究设计与样本
- 方法学框架研究,包含三个分析层级。
- Level 1 使用健康受试者 [123I]ioflupane SPECT 数据(n=224)建立 Centamine 量表。
- Level 2 使用 [123I]ioflupane SPECT 与 [18F]AV133 PET 头对头数据(n=68)进行映射分析。
主要发现
- Level 1 成功基于健康 [123I]ioflupane SPECT 扫描建立 Centamine 量表。
- [123I]ioflupane SPECT 与 [18F]AV133 PET 在 5 个脑区呈中强线性相关(R²=0.51-0.83)。
- 映射后的 Centamine 值在不同示踪剂间差异较小,范围从 1.5%(post-commissural putamen)到 3%(caudate)。
临床怎么用
- 该框架可用于统一不同多巴胺能成像示踪剂的区域结局指标,支持临床试验中的成像终点比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dopaminergic imaging is a key biomarker for both the investigation of the biology of Parkinson's disease and related synucleinopathies and the evaluation of potential therapies in clinical trials. This work presents a harmonized approach for quantifying dopaminergic molecular imaging tracers, such as [123I]ioflupane (dopamine transporter scan [DaTscan]) single photon emission computed tomography (SPECT) and [18F]AV133 positron emission tomography (PET), which assess dopaminergic neuronal loss. The proposed method aims to standardize regional outcome measures using a unified scale called Centamines. METHODS: The Centamines framework comprises 3 analysis levels. Level 1 defines the Centamine scale based on healthy subject data from [123I]ioflupane SPECT (n = 224). Level 2 uses head-to-head data between Tracer X and [123I]ioflupane SPECT to map Tracer X onto the Centamine scale. Level 3 maps additional tracers using prior mappings. A level 2 analysis was performed using [123I]ioflupane SPECT and [18F]AV133 PET data (n = 68) to convert [18F]AV133 PET into Centamines. RESULTS: Level 1 successfully established the Centamine scale using healthy [123I]ioflupane SPECT scans. Level 2 revealed moderate-strong linear correlations (R2 = 0.51-0.83) between [123I]ioflupane SPECT and [18F]AV133 PET across 5 brain regions. Mapped Centamine values showed minimal differences between tracers, ranging from 1.5% (post-commissural putamen) to 3% (caudate). INTERPRETATION: The Centamine scale holds promise for the harmonized quantification of dopaminergic neuronal imaging markers. The Centamine strategy would enable and accelerate clinical trials in Parkinson's disease using dopaminergic imaging outcomes. ANN NEUROL 2026;99:949-963.
引用
- Fan Z, Searle G, Rizzo G, et al. Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale. Ann Neurol. 2026. PMID: 41556298. doi:10.1002/ana.78116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。